We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.61B
AUM Growth
-$1.09B
Cap. Flow
-$352M
Cap. Flow %
-4.08%
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30

Top Buys

Rank Stock Value
1
OM icon
Outset Medical
OM
+$58.4M
2
BSX icon
Boston Scientific
BSX
+$41.2M
3
PACB icon
Pacific Biosciences
PACB
+$38.3M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$37.2M
5
CDNA icon
CareDx
CDNA
+$32.9M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$109M
2
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
+$75.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$73.9M
4
DHR icon
Danaher
DHR
+$66.3M
5
HUM icon
Humana
HUM
+$65.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Industrials 0.69%
3 Energy 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGHT icon
126
Sight Sciences
SGHT
$267M
$3.47M 0.04%
300,000
– –
KOS icon
127
Kosmos Energy
KOS
$1.56B
$2.96M 0.03%
412,000
+120,000
+41% +$612K
CELL
128
DELISTED
PhenomeX Inc. Common Stock
CELL
$2.74M 0.03%
385,014
– –
CYTK icon
129
Cytokinetics
CYTK
$11B
$2.54M 0.03%
+69,000
New +$2.45M
PFE icon
130
Pfizer
PFE
$140B
$2.41M 0.03%
46,500
-66,500
-59% -$3.45M
SNY icon
131
Sanofi
SNY
$104B
$2.24M 0.03%
+43,600
New +$2.25M
KYMR icon
132
Kymera Therapeutics
KYMR
$9.1B
$2.22M 0.03%
52,400
+3,400
+7% +$144K
SEER icon
133
Seer Inc
SEER
$108M
$2.08M 0.02%
136,133
– –
COR icon
134
Cencora
COR
$60.3B
$2.01M 0.02%
+13,000
New +$1.84M
ALKS icon
135
Alkermes
ALKS
$8.82B
$1.97M 0.02%
+75,000
New +$1.86M
SUPN icon
136
Supernus Pharmaceuticals
SUPN
$2.68B
$1.91M 0.02%
+59,000
New +$1.81M
RARE icon
137
Ultragenyx Pharmaceutical
RARE
$2.65B
$1.87M 0.02%
25,700
+4,700
+22% +$327K
BPMC
138
DELISTED
Blueprint Medicines
BPMC
$1.66M 0.02%
26,000
+500
+2% +$35.9K
PCRX icon
139
Pacira BioSciences
PCRX
$1.02B
$1.61M 0.02%
+21,136
New +$1.41M
BCYC
140
Bicycle Therapeutics
BCYC
$270M
$1.6M 0.02%
36,500
-17,200
-32% -$803K
CCCC icon
141
C4 Therapeutics
CCCC
$376M
$1.32M 0.02%
54,500
+7,300
+15% +$177K
MRTX
142
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.22M 0.01%
14,800
-6,800
-31% -$695K
NTLA icon
143
Intellia Therapeutics
NTLA
$1.5B
$1.18M 0.01%
16,294
-300
-2% -$25.4K
GTH
144
DELISTED
Genetron Holdings Limited ADS
GTH
$1.17M 0.01%
178,607
-62,439
-26% -$684K
LH icon
145
Labcorp
LH
$24.3B
$1.12M 0.01%
4,947
-4,889
-50% -$1.15M
XNCR icon
146
Xencor
XNCR
$1.44B
$1.11M 0.01%
41,600
-10,500
-20% -$339K
INBX
147
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.11M 0.01%
49,700
-800
-2% -$20.4K
ARCT icon
148
Arcturus Therapeutics
ARCT
$157M
$1.1M 0.01%
40,900
-700
-2% -$17.9K
KURA icon
149
Kura Oncology
KURA
$922M
$1.06M 0.01%
+65,980
New +$953K
QTRX icon
150
Quanterix
QTRX
$173M
$1.04M 0.01%
35,704
-361,760
-91% -$11.1M
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2022 Portfolio in Review

As of Q1 2022, Bellevue Group held 207 positions worth $8.61B, down 11% from $9.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group withdrew a net $352M in Q1 2022, closing 30 positions and reducing 80 holdings. Its most notable exit was VOCERA COMMUNICATIONS, INC., an estimated $75.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Aurinia Pharmaceuticals worth $29.8M.

  • Bellevue Group's largest Q1 2022 buy was Aurinia Pharmaceuticals: 2,405,825 shares worth $29.8M.
  • Bellevue Group added most to Outset Medical in Q1 2022, an estimated $58.4M increase.
  • Bellevue Group's biggest Q1 2022 reduction was Biogen, cutting an estimated $109M.
  • Bellevue Group fully exited VOCERA COMMUNICATIONS, INC. in Q1 2022, selling an estimated $75.3M.
  • Bellevue Group's ten largest holdings make up 31% of its $8.61B portfolio in Q1 2022.
  • Bellevue Group opened 16 new positions and closed 30 in Q1 2022.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $8.61B.

Based on Bellevue Group's 13F filing for Q1 2022, filed 13 May 2022.